Prospira ENT Revenue

About Prospira ENT

Prospira is developing a bioabsorbable implant that delivers long-lasting mometasone directly into the inferior turbinate, providing up to six months of relief for patients with moderate to severe seasonal allergies. Designed as a simple, 15-minute in-office procedure, the implant offers a convenient alternative to daily nasal sprays, significantly improving adherence and patient outcomes. By targeting local inflammation directly within the turbinate, Prospira minimizes systemic side effects while delivering sustained therapeutic benefits. The platform builds on the established practice of delivering steroids into the turbinate, addressing previous risks associated with liquid injections and enabling longer-term relief. What sets Prospira apart is its innovative drug delivery platform, which leverages biodegradable materials for precise, controlled elution of mometasone over time. This unique approach creates a seamless patient experience and introduces a new treatment paradigm for allergists, ENT specialists, and general practitioners. With strong intellectual property, a clear regulatory pathway via the 505(b)(2) process, and established reimbursement codes, Prospira is poised to disrupt the $24 billion allergy market and fulfill the unmet need for effective, long-lasting allergy relief

View contact profiles from Prospira ENT